Prime Medicine, Inc. Common Stock
Here’s whether Prime Medicine, Inc. Common Stock (PRME) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.29% over 10 days); RSI 64 — healthy momentum range; 3-month momentum positive (+14.1%). Concerns: trading below the 200-day MA (long-term downtrend). Currently 51.1% off its 52-week high. Score: +2/7.
PRME is trading below its 200-day MA ($3.56) — a key warning sign the longer-term trend is under pressure. An RSI of 64.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +5.3% compares to +20.5% for SPY (trailed the market by 15.2%). The current 51.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.